Nkarta – Allogeneic CAR Natural Killer (NK) Cell Therapy
Paul Hastings, CEO of Nkarta Therapeutics discusses results from their NKX101 study, an allogeneic CAR Natural Killer (NK) cell therapy, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS).
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Paul is the President and Chief Executive Officer of Nkarta, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer. After beginning his career in sales and marketing at Hoffman-LaRoche, he has led more than a dozen biopharma companies as CEO, President or Director. He currently serves as Vice Chair and member of the Executive Committee of BIO.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
